✦ Dec. 14: The FDA granted an additional indication to Nplate (romiplostim) for the treatment of patients at least one year old with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immune globulins or splenectomy. The agency initially approved the Amgen Inc. product in August 2008 to treat adults with chronic ITP (RSP 9/08, p. 7). The current application had orphan product designation.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.